Skip to main content
SpringerLink
Log in

Development of Dendritic Cell-Based Prostate Cancer Vaccine

  • Chapter
Prostate Cancer

Part of the book series: Contemporary Cancer Research ((CCR))

  • 175 Accesses

Abstract

Current prostate cancer treatments include surgery, radiotherapy, chemotherapy, and hormone therapy. Efforts in early detection of prostate cancer—which include serum prostate specific antigen (PSA) screening and digital rectal examination—have allowed for diagnoses of the disease at its earliest stages. Treatment strategies such as radical prostatectomy and local radiotherapy are largely successful for patients with clinically localized prostate cancer (14,32,64). Brachytherapy is an example of a novel method to introduce radioisotopes to localized cancer tissues (40). This method implants radioactive seeds directly into tumor sites, minimizing exposure to surrounding tissues. A 10-yr follow-up study involving brachytherapy treatment of 152 consecutive patients with clinically organ confined prostate carcinoma reported a disease-free rate of 64% (41). However, up to one-third of patients initially diagnosed with clinically localized disease and treated with conventional treatments may eventually develop metastases (20).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander, M., M. L. Salgaller, E. Celis, A. Sette, W. A. Barnes, S. A. Rosenberg, et al. 1996. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol. 175: 1586–1593.

    Article  PubMed  CAS  Google Scholar 

  2. Austyn, J. 1996. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 180: 1287–1292.

    Article  Google Scholar 

  3. Berhard, H., M. L. Disis, S. Heimfeld, S. Hand, J. R. Gralow, and M. A. Cheever. 1995. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55: 1099–1104.

    Google Scholar 

  4. Cormier, J. N., M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, et al. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1 /Melan A. Cancer J. Sci. Am. 3: 37–44.

    PubMed  CAS  Google Scholar 

  5. DeVita, Jr., V. 1997. Principles of chemotherapy, in Cancer Principles & Practice of Oncology ( DeVita, Jr., S. Hellman, and S. Rosenberg, eds.), Lippincott, Philadelphia, PA, p. 276.

    Google Scholar 

  6. Engelhard, V. H. 1994. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 12: 181–207.

    Article  PubMed  CAS  Google Scholar 

  7. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M. Bakkus, H. Bazin, et al. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24: 605–610.

    Article  PubMed  CAS  Google Scholar 

  8. Foti, A. G., J. F. Cooper, H. Herschman, and R. R. Malvaez. 1977. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N. Engl. J. Med. 297: 1357–1361.

    Article  PubMed  CAS  Google Scholar 

  9. Fung, P. Y. S., M. Madej, R. R. Koganty, and B. M. Longenecker. 1992. Active specificimmunotherapy of a murine mammary adenocarcinoma using a specific tumor-associated glycoconjugate. Cancer Res. 50: 4308–4311.

    Google Scholar 

  10. Grabbe, S., S. Beissert, T. Schwarz, and R. D. Granstein. 1995. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16: 117–121.

    CAS  Google Scholar 

  11. Grabbe, S., S. Bruvers, R. L. Gallo, T. L. Knisely, R. Nazareno, and R. D. Grandstein. 1991. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146: 3656–3661.

    PubMed  CAS  Google Scholar 

  12. Gupta, R. K. and G. R. Siber. 1995. Adjuvants for human vaccines-current status, problems, and future prospects. Vaccine 13: 1263–1276.

    Article  PubMed  CAS  Google Scholar 

  13. Gupta, R. K., C. L. Varanelli, P. Griffin, D. F. Wallach, and G. R. Siber. 1996. Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens (published erratum appears in Vaccine 1996 Jun;14[8]:1). Vaccine 14: 219–225.

    Article  PubMed  CAS  Google Scholar 

  14. Hanks, G., J. Krall, A. Hanlon, S. Asbell, M. Pilepich, and J. Owen. 1994. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int. J. Radiat. Oncol. Biol. Phys. 28: 39–45.

    Article  PubMed  CAS  Google Scholar 

  15. Helling, F., S. Zhang, A. Shang, S. Adluri, M. Calves, R. Koganty, et al. 1995. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55: 2783–2788.

    PubMed  CAS  Google Scholar 

  16. Horoszewicz, J. S., E. Kawinski, and G. P. Murphy. 1987. Monoclonal antibodies to a new antigenic marker in epithelial prostate cells and serum of prostatic cancer patients. Anticancer Res. 7: 927–936.

    PubMed  CAS  Google Scholar 

  17. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52–28.

    Google Scholar 

  18. Israeli, R. S., C. T. Powell, J. G. Con, W. R. Fair, and W. Heston. 1993. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 54: 1807–1811.

    Google Scholar 

  19. Iverson, P. 1998. Orchidectomy and oestrogen therapy revisited. Eur. Urol. 34 (Suppl.): 7–11.

    Article  Google Scholar 

  20. Jones, G., C. Mettlin, G. Murphy, P. Guinan, H. Herr, D. Hussey, et al. 1995. Patterns of care for carcinoma of the prostate gland; results of a national survey of 1984 and 1990. J. Am. Coll. Surg. 545–554.

    Google Scholar 

  21. Kappler, J. N. Roehm, and P. T. Marrack. 1987. Cell tolerance by clonal elimination in the thymus. Cell 49: 273–280.

    Google Scholar 

  22. Kawakami, M. and J. Nakayama. 1997. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 15: 2321–2324.

    Google Scholar 

  23. Knight, S. C. and A. J. Stagg. 1993. Antigen-presenting cell types. Curr. Opin. Immunol. 5: 374–382.

    Article  PubMed  CAS  Google Scholar 

  24. Knight, S. C., R. Hunt, C. Dore, and P. B. Medawar. 1985. Influence of dendritic cells on tumor growth. Proc. Natl. Acad. Sci. USA 82: 4495–4497.

    Article  PubMed  CAS  Google Scholar 

  25. Krikorian, J., C. Portlock, D. Cooney, and S. Rosenberg. 1980. Spontaneous regression of non-Hodgkin’s lymphoma. A report of nine cases. Cancer 46: 2093–2099.

    Article  PubMed  CAS  Google Scholar 

  26. Lindhout, E., C. G. Figdor, and G. J. Adema. 1998. Dendritic cells: migratory cells that are attractive. Cell Adhes. Commun. 6: 117–123.

    Article  PubMed  CAS  Google Scholar 

  27. Maraskovsky, E., McKenna, H., and Brasel, K. 1995. In vivo administration of Flt3 ligand but not G-CSF nor GM-CSF results in the generation of large numbers of dendritic cells in mice. Blood 86: 423a (Abstract 1680 ).

    Google Scholar 

  28. Marrack, P. and J. Kappler. 1987. The T cell receptor. Science 238: 1073–1079.

    Article  PubMed  CAS  Google Scholar 

  29. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1: 1297–1302.

    Article  PubMed  CAS  Google Scholar 

  30. Melder, R. J., T. L. Whiteside, N. L. Vujanovic, J. C. Hiserodt, and R. B. Herberman. 1988. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res. 48: 3461–3469.

    PubMed  CAS  Google Scholar 

  31. Mellman, I., S. J. Turley, and R. M. Steinman. 1998. Antigen processing for amateurs and professionals. Trends Cell Biol. 8: 231–237.

    Article  PubMed  CAS  Google Scholar 

  32. Middleton, R., J. Smith, R. Melzer, and P. Hamilton. 1986. Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J. Urol. 136: 422–424.

    PubMed  CAS  Google Scholar 

  33. Mitropoulos, D., S. Kooi, J. Rodriguez-Villanueva, and C. D. Platsoucas. 1994. Characterization of fresh (uncultured) tumour-inflitrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin. Exp. Immunol. 97: 321–327.

    Article  PubMed  CAS  Google Scholar 

  34. Murphy, G. P., B. A. Tjoa, S. J. Simmons, J. Jarisch, V. A. Bowes, H. Ragde, et al. 1999. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory prostate cancer. Prostate 38: 73–78.

    Article  PubMed  CAS  Google Scholar 

  35. Murphy, G. P., B. A. Tjoa, S. J. Simmons, H. Ragde, M. Rogers, A. Elgamal, et al. 1999. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment [In Process Citation]. Prostate 39: 54–59.

    Article  PubMed  CAS  Google Scholar 

  36. Murphy, G., H. Ragde, G. Kenny, R. Barren III, S. Erickson, B. Tjoa, et al. 1995. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 15: 1473–1480.

    PubMed  CAS  Google Scholar 

  37. Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201specific peptides from prostate-specific membrane antigen. Prostate 29: 371–380.

    Article  PubMed  CAS  Google Scholar 

  38. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, et al. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328–332.

    Article  PubMed  CAS  Google Scholar 

  39. Oh, W. K. and P. W. Kantoff. 1998. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol. 160: 1220–1229.

    Article  PubMed  CAS  Google Scholar 

  40. Ragde, H. 1997. Brachytherapy (seed implantation) for clinically localized prostate cancer. J. Surg. Oncol. 64: 79–81.

    Article  PubMed  CAS  Google Scholar 

  41. Ragde, H., A. Elgamal, P. Snow, J. Brandt, A. Bartolucci, B. Nadir, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83: 989–1001.

    Google Scholar 

  42. Ralfkiaer, E., K. Hou-Jensen, K. Gatter, D. Drzewiecki, and D. Mason. 1987. Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas. Virchows Arch. 410: 355–361.

    Article  CAS  Google Scholar 

  43. Ravindranath, M. H., D. L. Morton, and R. F. Irie. 1989. An epitope common to ganglio-sides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res. 49: 3891–3897.

    PubMed  CAS  Google Scholar 

  44. Romani, N., D. Reider, M. Heuer, S. Ebner, and E. Kempgen. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196: 137–151.

    Article  PubMed  CAS  Google Scholar 

  45. Rosenberg, S. A. 1996. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88: 1635–1644.

    Article  PubMed  CAS  Google Scholar 

  46. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319: 1676–1680.

    Article  PubMed  CAS  Google Scholar 

  47. Ruiter, D. J., A. K. Bhan, T. J. Harrist, A. J. Sober, and M. Mhim-Jr. 1982. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferation and malignant melanoma. J. Immunol. 129: 2808–2815.

    PubMed  CAS  Google Scholar 

  48. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56: 4749–4757.

    PubMed  CAS  Google Scholar 

  49. Sallusto, F. and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179: 1109–1118.

    Article  PubMed  CAS  Google Scholar 

  50. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J. Exp. Med. 182: 389–400.

    Article  PubMed  CAS  Google Scholar 

  51. Scher, H. I., G. Steineck, and W. K. Kelly. 1995. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46: 142–148.

    Article  PubMed  CAS  Google Scholar 

  52. Sedlacek, H. 1994. Vaccination for treatment of tumors: a critical comment. Critical Rev. Oncog. 5: 555–587.

    CAS  Google Scholar 

  53. Siegall, C. B. 1994. Targeted toxins as anticancer agents. Cancer 74: 1006–1012.

    Article  PubMed  CAS  Google Scholar 

  54. Simmons, S. J., B. A. Tjoa, M. Rogers, A. Elgamal, G. M. Kenny, H. Ragde, et al. 1999. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 39: 291–297.

    Article  PubMed  CAS  Google Scholar 

  55. Slovin, S. F., W. K. Kelly, and H. I. Scher. 1998. Immunological approaches for the treatment of prostate cancer. Sem. Urol. Oncol. 16: 53–59.

    CAS  Google Scholar 

  56. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271–296.

    Article  PubMed  CAS  Google Scholar 

  57. Thomas, R., L. S. Davis, and P. E. Lipsky. 1993. Isolation and characterization of human peripheral blood dendritic cells. J. Immunol. 150: 821–829.

    PubMed  CAS  Google Scholar 

  58. Tjoa, B. A., S. J. Simmons, A. Elgamal, M. Rogers, H. Ragde, G. M. Kenny, et al. 1999. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40: 125–129.

    Article  PubMed  CAS  Google Scholar 

  59. Tjoa, B., S. Erickson, R. Barren III, H. Ragde, G. Kenny, A. Boynton, et al. 1995. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 27: 63–69.

    Article  PubMed  CAS  Google Scholar 

  60. Tjoa, B., S. Erickson, V. Bowes, H. Ragde, G. Kenny, O. Cobb, et al. 1997. Follow-up evaluation of prostate cancer patients with autologous dendritic cells pulsed with PSMA peptides. Prostate 32: 272–278.

    Article  PubMed  CAS  Google Scholar 

  61. Tjoa, B., S. Simmons, V. Bowes, H. Ragde, M. Rogers, A. Elgamal, et al. 1998. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36: 39–44.

    Article  PubMed  CAS  Google Scholar 

  62. Topalian, S., D. Solomon, F. P. Avis, A. E. Chang, D. L. Freerksen, W. M. Linehan, et al. 1988. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J. Clin. Oncol. 6: 839–853.

    PubMed  CAS  Google Scholar 

  63. Urban, J. L. and H. Schreiber. 1992. Tumor antigens. Ann. Rev. Immunol. 10: 617–644.

    Article  CAS  Google Scholar 

  64. Walsh, P. C., A. W. Partin, and J. I. Epstein. 1994. Cancer control and quality of life following anatomic radical retropubic prostatectomy. Results at 10 years. J. Urol. 152: 1831–1836.

    PubMed  CAS  Google Scholar 

  65. Wang, M., L. Valenzuela, G. Murphy, and T. Chu. 1979. Purification of a human prostate-specific antigen. Investig. Urol. 17: 159–163.

    CAS  Google Scholar 

  66. Young, J. W. and R. M. Steinman. 1990. Dendritic cells stimulate primary human cytolytic lymphocyte response in the absence of CD4+ helper T cells. J. Exp. Med. 171: 1315–1332.

    Article  PubMed  CAS  Google Scholar 

  67. Zinkernagel, R. M. and P. C. Doherty. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248: 701, 702.

    Google Scholar 

Download references

Authors
  1. Benjamin A. Tjoa PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerald P. Murphy MD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Virginia School of Medicine, Charlottesville, VA, USA

    Leland W. K. Chung PhD

  2. The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    William B. Isaacs PhD

  3. The Johns Hopkins Hospital, Baltimore, MD, USA

    Jonathan W. Simons MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tjoa, B.A., Murphy, G.P. (2001). Development of Dendritic Cell-Based Prostate Cancer Vaccine. In: Chung, L.W.K., Isaacs, W.B., Simons, J.W. (eds) Prostate Cancer. Contemporary Cancer Research. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-009-4_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-009-4_26

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6304-1

  • Online ISBN: 978-1-59259-009-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation